Daily Respiratory Research Analysis
Analyzed 135 papers and selected 3 impactful papers.
Summary
Top advances span mechanistic fibrosis biology, antimicrobial development, and host–microbiome protection against post-viral lung infections. A Science Advances study defines a PARP1–FOXN3–p38 feedback axis that restrains Smad signaling and myofibroblast activation in pulmonary fibrosis. In EBioMedicine, multicentre preclinical profiling supports apramycin as a potent alternative to amikacin for nontuberculous mycobacteria, including M. abscessus. Science Immunology reveals gut SFB-driven reprogramming of alveolar macrophages that limits post-influenza bacterial pneumonia.
Research Themes
- Mechanistic regulation of pulmonary fibrosis via PARP1–FOXN3–p38–Smad axis
- Next-generation aminoglycoside therapy for nontuberculous mycobacterial lung disease
- Gut–lung axis: microbiome-driven protection against secondary bacterial pneumonia
Selected Articles
1. PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation.
This mechanistic study uncovers a PARP1–FOXN3–p38 feedback circuit that restrains Smad signaling and fibrogenesis. Lung-specific PARP1 loss destabilizes FOXN3, elevates p38, and drives myofibroblast activation, while FOXN3 overexpression rescues fibrosis. Patient data corroborate reduced PARP1/FOXN3 in pulmonary fibrosis.
Impact: Identifies a druggable regulatory axis in pulmonary fibrosis linking PARP1 to FOXN3 stability and Smad signaling control. Provides in vivo causal evidence and human relevance for a new antifibrotic target.
Clinical Implications: Targeting PARP1–FOXN3–p38 signaling may offer a novel antifibrotic strategy, potentially complementing or enhancing existing therapies (e.g., nintedanib, pirfenidone). Biomarker development for PARP1/FOXN3 could enable patient stratification.
Key Findings
- PARP1 binds and stabilizes FOXN3 by preventing p38-mediated phosphorylation and degradation.
- Lung-specific PARP1 knockout increases fibrosis by lowering FOXN3 and enhancing Smad signaling; FOXN3 overexpression mitigates this.
- PARP1–FOXN3 complex transcriptionally represses p38; disruption triggers a feedback loop that accelerates FOXN3 loss and fibrogenesis.
- PARP1 and FOXN3 protein levels are reduced in lungs from patients with pulmonary fibrosis.
Methodological Strengths
- Genetic causality via lung-specific PARP1 knockout and FOXN3 rescue models.
- Mechanistic dissection of transcriptional feedback with pathway mapping and patient validation.
Limitations
- Preclinical models; lack of interventional human trials targeting this axis.
- Potential tissue- and species-specific context may affect translational generalizability.
Future Directions: Evaluate pharmacologic modulation of PARP1–FOXN3–p38 in large-animal models; develop biomarkers for PARP1/FOXN3; explore combinatorial strategies with approved antifibrotics.
The transcriptional repressor forkhead box N3 (FOXN3) has been reported to suppress pulmonary fibrosis by inhibiting Smad transcriptional activity. However, FOXN3 becomes unstable in response to profibrotic stimuli. This study identifies poly(ADP-ribose) polymerase-1 (PARP1) as a stabilizing partner of FOXN3, preventing its degradation by blocking p38-mediated phosphorylation. Lung-specific knockout (KO) of PARP1 promotes the development of pulmonary fibrosis by reducing the abundance of FOXN3. Conditional overexpression of FOXN3 notably mitigates pulmonary fibrosis resulting from PARP1 KO by impeding Smad signaling, underscoring the critical role of the PARP1-FOXN3 axis in pulmonary fibrosis. Mechanistically, p38 is a Smad response gene that is transcriptionally repressed by the PARP1/FOXN3 complex. The disruption of PARP1 or FOXN3 increases p38 expression, which in turn facilitates FOXN3 degradation through a feedback mechanism. This cascade activates Smad signaling, leading to a profibrotic response and myofibroblast activation. Notably, levels of PARP1 and FOXN3 are significantly reduced in patients with pulmonary fibrosis, highlighting PARP1's crucial role in suppressing the disease by regulating FOXN3-mediated Smad signaling.
2. Segmented filamentous bacteria reprogramming of alveolar macrophages limits postinfluenza bacterial pneumonia.
In murine models, intestinal SFB colonization reprograms alveolar macrophages to resist depletion after influenza, thereby reducing susceptibility to secondary bacterial pneumonia. The gut–lung axis emerges as a modifiable determinant of post-viral bacterial superinfection risk.
Impact: Reveals a microbiome-driven, mechanistic means to prevent lethal post-influenza bacterial pneumonia by programming resident lung immunity. Highlights preventive strategies beyond antibiotics/vaccines.
Clinical Implications: Microbiome-based interventions (e.g., safe SFB surrogates or targeted microbial metabolites) could bolster alveolar macrophage resilience post-influenza, reducing secondary bacterial pneumonia. May inform timing of prophylaxis in high-risk patients.
Key Findings
- Intestinal SFB colonization reprograms alveolar macrophages to resist depletion after influenza infection.
- SFB-induced AM reprogramming reduces susceptibility to secondary bacterial pneumonia in mice.
- Demonstrates a causal gut–lung axis mechanism for mitigating post-viral bacterial superinfection risk.
Methodological Strengths
- In vivo influenza–bacteria superinfection model with mechanistic immune cell reprogramming readouts.
- Causal linkage of gut colonization to lung macrophage phenotype and host protection.
Limitations
- SFB are murine-specific commensals; translational surrogates for humans are required.
- Preclinical findings require validation in human-relevant systems and safety assessment.
Future Directions: Identify human-translatable microbial species/metabolites that mimic SFB effects; evaluate prophylactic efficacy in diverse viral–bacterial combinations and comorbid conditions.
Respiratory viral infection induces depletion and dysfunction of alveolar macrophages (AMs), resulting in high-susceptibility to life-threatening bacterial pneumonia. Colonization of the intestine by segmented filamentous bacteria (SFB) reprograms AM to resist depletion. Hence, we examined whether SFB protected mice against secondary bacterial infection by
3. Multicentre preclinical profiling of apramycin for the treatment of nontuberculous mycobacteria.
Across 828 NTM isolates and multiple assay conditions, apramycin demonstrated potent activity against clinically important species, including M. abscessus, with supportive in vivo efficacy. Data support apramycin as a promising alternative to amikacin for NTM lung disease.
Impact: Addresses a critical therapeutic gap in drug-resistant NTM, providing broad preclinical evidence for a next-generation aminoglycoside poised for clinical translation.
Clinical Implications: Apramycin may expand effective options for M. abscessus complex lung disease, particularly in cystic fibrosis and bronchiectasis. Findings justify PK/PD-guided dose-finding and safety studies to enable clinical trials.
Key Findings
- Apramycin exhibited strong in vitro activity across 828 NTM isolates, including M. abscessus and M. chelonae.
- Bactericidal activity and favorable killing kinetics were demonstrated under varied assay conditions.
- In vivo efficacy supported translational potential against rough and smooth M. abscessus.
- Comparative profiling supports apramycin as a viable alternative to amikacin.
Methodological Strengths
- Large, multicentre isolate panel (n=828) spanning clinically relevant NTM species.
- Integrated in vitro and in vivo assessment including killing kinetics across phenotypes.
Limitations
- Preclinical study; human PK/PD, safety, and efficacy data are pending.
- Resistance emergence and ototoxicity/nephrotoxicity profiles require careful clinical evaluation.
Future Directions: Conduct dose-ranging and safety trials with PK/PD modeling; evaluate efficacy in CF and non-CF bronchiectasis NTM cohorts; investigate resistance mechanisms.
BACKGROUND: Current treatment regimens for nontuberculous mycobacteria (NTM) infections, especially Mycobacterium abscessus, have suboptimal clinical outcomes, demanding novel therapeutic options. The aminoglycoside apramycin (APR) has been suggested as a therapeutic alternative to amikacin (AMK). Here, we report experimental data as part of an ongoing preclinical assessment of APR. METHODS: Antimicrobial activity against 828 isolates comprising the clinically most relevant NTM species were determined by broth microdilution. Bactericidal activity and killing kinetics of APR were determined across a variety of assay conditions against rough and smooth M. abscessus isolates in vitro and in vivo. FINDINGS: Both the MIC INTERPRETATION: For M. abscessus and M. chelonae, the APR MIC FUNDING: This study was supported by the Cystic Fibrosis Foundation (CFF) Therapeutic Development Award JUVABIS22W0 and CFF grant HOBBIE19I0.